Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Bizengri (zenocutuzumab-zbco)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Merus, Partner Therap

Drug class:

HER2 inhibitor, HER3 inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

Ac-225 ErbB3 targeted radiotherapy (4)

177Lu-HER3 ARC (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

mobocertinib (12)

trastuzumab-dttb (11)

zanidatamab-hrii (10)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

Ac-225 ErbB3 targeted radiotherapy (4)

177Lu-HER3 ARC (0)

›

NRG1 fusion	Solid Tumor	NRG1 fusion	Solid Tumor	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B
NRG1 fusion	Pancreatic Cancer	NRG1 fusion	Pancreatic Cancer	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B
NRG1 fusion	Non Small Cell Lung Cancer	NRG1 fusion	Non Small Cell Lung Cancer	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B
NRG1 fusion	Pancreatic Ductal Adenocarcinoma	NRG1 fusion	Pancreatic Ductal Adenocarcinoma	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B
NRG1 fusion	Pancreatic Cancer	NRG1 fusion	Pancreatic Cancer	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2
NRG1 fusion	Cholangiocarcinoma	NRG1 fusion	Cholangiocarcinoma	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2
NRG1 fusion	Breast Cancer	NRG1 fusion	Breast Cancer	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3
ATP1B1-NRG1 fusion	Pancreatic Cancer	ATP1B1-NRG1 fusion	Pancreatic Cancer	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab + zenocutuzumab-zbco Sensitive: C3 – Early Trials trastuzumab + zenocutuzumab-zbco Sensitive : C3	trastuzumab + zenocutuzumab-zbco Sensitive: C3 – Early Trials trastuzumab + zenocutuzumab-zbco Sensitive : C3
CD74-NRG1 fusion	Non Small Cell Lung Cancer	CD74-NRG1 fusion	Non Small Cell Lung Cancer	zenocutuzumab-zbco Sensitive: C4 – Case Studies zenocutuzumab-zbco Sensitive : C4	zenocutuzumab-zbco Sensitive: C4 – Case Studies zenocutuzumab-zbco Sensitive : C4
SLC3A2-NRG1 fusion	Estrogen Receptor Positive Breast Cancer	SLC3A2-NRG1 fusion	Estrogen Receptor Positive Breast Cancer	zenocutuzumab-zbco Sensitive: C4 – Case Studies zenocutuzumab-zbco Sensitive : C4	zenocutuzumab-zbco Sensitive: C4 – Case Studies zenocutuzumab-zbco Sensitive : C4
CLU-NRG1 fusion	Ovarian Cancer	CLU-NRG1 fusion	Ovarian Cancer	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D
SLC3A2-NRG1 fusion	Ovarian Cancer	SLC3A2-NRG1 fusion	Ovarian Cancer	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D